Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug

Clene Inc. shares rose 6.68% after the company said it is filing for accelerated FDA approval of its ALS treatment following a constructive meeting with regulators. The update is positive for the drug's regulatory path and supports the company's fundamentals, though it remains a development-stage biotech event rather than a broad market catalyst.

Analysis

Clene Inc. shares rose 6.68% after the company said it is filing for accelerated FDA approval of its ALS treatment following a constructive meeting with regulators. The update is positive for the drug's regulatory path and supports the company's fundamentals, though it remains a development-stage biotech event rather than a broad market catalyst.